Pharma's Almanac | Catalent

36 Articles Available

1 2

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

PAO-09-23-RT-01

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

PAO-09-23-RT-02

Roundtable: Artificial Intelligence

In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?

PAO-07-23-RT-01

Roundtable: Patient Centricity

How is an increased focus on patient-centric concerns influencing the way that you work?

PAO-07-23-RT-02

Future of the Industry

What key indicators do you look at to predict the future of this industry?

PAO-10-022--RT-02

Sustainability

What is your plan to build a more sustainable business practice in the coming years?

PAO-10-022--RT-01

2021 Roundup: The Year of Cell and Gene Therapy

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Gene Therapy

Planning for Success, Addressing Quality Early for Gene Therapies

PAO-05-21-CL-02

Clinical Trial Logistics

Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies

PAO-03-21-CL-06

Chemistry, Manufacturing, and Controls

Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization

PAO-01-21-CL-05

Cell Therapy

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

PAO-12-20-CL-01

COVID-19 vaccine

How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships

PAP-Q4-20-CL-007

Clinical Supply

Getting Your Biologic to Clinic Faster and More Efficiently

PAP-Q3-20-CL-011

COVID-19 Vaccine

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

PR-M08-20-NI-41

Expansion

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

PR-M08-20-NI-13

COVID-19 Vaccine

Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

PR-M04-20-NI-044

FDA Approval

Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA

PR-M02-20-NI-041

M&A

Catalent Completes Acquisition of MaSTherCell

PR-M02-20-NI-014

M&A

Catalent Acquires Orgenesis' Cell Therapy Unit

PR-M01-20-NI-046

Integration

Building Upon an Integrated Biologics Offering

PTV-M08-19-BIO-005

Partnership

Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing

PR-M07-19-NI-014

Strategic Partnership

Novavax and Catalent Biologics Enter Strategic Partnershipto Expand Gene Therapy Footprint

PR-M07-19-NI-001

Strategic Relationship

IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases

PR-M06-19-NI-034

1 2

Catalent

36 Articles Available

Can't find what you're looking for? Try our advanced search.

Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

Industry Wisdom

What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?

Roundtable: Artificial Intelligence

In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?

Roundtable: Patient Centricity

How is an increased focus on patient-centric concerns influencing the way that you work?

Future of the Industry

What key indicators do you look at to predict the future of this industry?

Sustainability

What is your plan to build a more sustainable business practice in the coming years?

2021 Roundup: The Year of Cell and Gene Therapy

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Gene Therapy

Planning for Success, Addressing Quality Early for Gene Therapies

Clinical Trial Logistics

Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies

Chemistry, Manufacturing, and Controls

Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization

Cell Therapy

Allogeneic T Cell Therapies: Efficient Commercial Manufacturing Readiness using “Manufacturing by Design” Methodology

COVID-19 vaccine

How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Partnerships

Clinical Supply

Getting Your Biologic to Clinic Faster and More Efficiently

COVID-19 Vaccine

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

Expansion

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

COVID-19 Vaccine

Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate

FDA Approval

Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA

M&A

Catalent Completes Acquisition of MaSTherCell

M&A

Catalent Acquires Orgenesis' Cell Therapy Unit

Integration

Building Upon an Integrated Biologics Offering

Partnership

Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing

Strategic Partnership

Novavax and Catalent Biologics Enter Strategic Partnershipto Expand Gene Therapy Footprint

Strategic Relationship

IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases